Keck School of Medicine of USC has embarked on a collaboration with Autobahn Labs, an accelerator for early-stage drug discovery, to identify and advance cutting-edge scientific findings into new therapies - with a special focus on critical unmet medical needs. By leveraging USC’s scientific expertise and Autobahn’s drug discovery capabilities, the collaboration is expected to accelerate the development of novel therapeutics that address critical medical needs and improve patient outcomes. As part of the agreement with USC, Autobahn will invest up to $5 million per selected project to support the development of new pharmaceuticals.

About The Study: In this cohort study, racial and ethnic disparities in early-onset (before 50 years of age) colorectal cancer mortality were evident, with the highest burden among Native Hawaiian or Other Pacific Islander and non-Hispanic Black individuals. These results provide evidence of the role of social determinants of health in explaining these differences.

The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) announces new appointments of cancer researchers to lead committees in its expansive scientific program. ECOG-ACRIN is at the forefront of research spanning the cancer care spectrum, from early detection to management of advanced disease. These impactful appointments, which are effective immediately, underscore the group’s commitment to wide-ranging cancer research excellence and premier professional opportunities for researchers. 

LMU researchers have discovered how the interplay between a key protein and an endolysosomal ion channel promotes tumor development in skin cancer.

The standard treatment for head and neck cancer, cisplatin, can’t be given to some patients due to pre-existing conditions. A new study compares the efficacy of two alternatives: cetuximab, a monoclonal antibody, and durvalumab, an immune checkpoint inhibitor.